000061676 001__ 61676
000061676 005__ 20230421130005.0
000061676 0247_ $$2doi$$a10.1016/j.vaccine.2013.07.051
000061676 0248_ $$2sideral$$a85742
000061676 037__ $$aART-2013-85742
000061676 041__ $$aeng
000061676 100__ $$aArbues, Ainhoa
000061676 245__ $$aConstruction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials
000061676 260__ $$c2013
000061676 5060_ $$aAccess copy available to the general public$$fUnrestricted
000061676 5203_ $$aThe development of a new tuberculosis vaccine is an urgent need due to the failure of the current vaccine, BCG, to protect against the respiratory form of the disease. MTBVAC is an attenuated Mycobacterium tuberculosis vaccine candidate genetically engineered to fulfil the Geneva consensus requirements to enter human clinical trials. We selected a M. tuberculosis clinical isolate to generate two independent deletions without antibiotic-resistance markers in the genes phoP, coding for a transcription factor key for the regulation of M. tuberculosis virulence, and fadD26, essential for the synthesis of the complex lipids phthiocerol dimycocerosates (DIM), one ofthe major mycobacterial virulence factors. The resultant strain MTBVAC exhibits safety and biodistribution profiles similar to BCG and confers superior protection in preclinical studies. These features have enabled MTBVAC to be the first live attenuated M. tuberculosis vaccine to enter clinical evaluation.
000061676 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/BIO2011-23555$$9info:eu-repo/grantAgreement/ES/MINECO/BIO2008-01561$$9info:eu-repo/grantAgreement/ES/MINECO/BES-2006-11950$$9info:eu-repo/grantAgreement/ES/MICINN/Juan de la Cierva Program-JCI-2009-03799$$9info:eu-repo/grantAgreement/EC/FP7/241745/EU/Discovery and preclinical development of new generation tuberculosis vaccines/NEWTBVAC
000061676 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000061676 590__ $$a3.485$$b2013
000061676 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b35 / 124 = 0.282$$c2013$$dQ2$$eT1
000061676 591__ $$aIMMUNOLOGY$$b53 / 144 = 0.368$$c2013$$dQ2$$eT2
000061676 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000061676 700__ $$0(orcid)0000-0001-7897-9173$$aAguilo, Juan I.$$uUniversidad de Zaragoza
000061676 700__ $$0(orcid)0000-0001-8841-6593$$aGonzalo-Asensio, Jesús$$uUniversidad de Zaragoza
000061676 700__ $$aMarinova, Dessislava
000061676 700__ $$aUranga, Santiago
000061676 700__ $$aPuentes, Eugenia
000061676 700__ $$aFernández, Conchita
000061676 700__ $$aParra, Alberto
000061676 700__ $$aCardona, Pere Joan
000061676 700__ $$aVilaplana, Cristina
000061676 700__ $$aAusina, Vicente
000061676 700__ $$aWilliams, Ann
000061676 700__ $$aClark, Simon
000061676 700__ $$aMalaga, Wladimir
000061676 700__ $$aGuilhot, Christophe
000061676 700__ $$aGicquel, Brigitte
000061676 700__ $$0(orcid)0000-0003-2993-5478$$aMartin, Carlos$$uUniversidad de Zaragoza
000061676 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000061676 773__ $$g31, 42 (2013), 4867-4873$$pVaccine$$tVACCINE$$x0264-410X
000061676 8564_ $$s1841361$$uhttps://zaguan.unizar.es/record/61676/files/texto_completo.pdf$$yPostprint
000061676 8564_ $$s91032$$uhttps://zaguan.unizar.es/record/61676/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000061676 909CO $$ooai:zaguan.unizar.es:61676$$particulos$$pdriver
000061676 951__ $$a2023-04-21-12:39:25
000061676 980__ $$aARTICLE